Company Overview of Cardiome Pharma Corp.
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It has operations in Canada, the United States, and Europe. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.
1441 CREEKSIDE DRIVE
Vancouver, BC V6J 4S7
Founded in 1986
Key Executives for Cardiome Pharma Corp.
Chief Executive Officer, President and Director
Total Annual Compensation: $650.0K
Chief Financial Officer
Total Annual Compensation: $275.0K
Chief Operating Officer
Total Annual Compensation: $240.0K
Corporate General Counsel
Total Annual Compensation: $248.5K
Compensation as of Fiscal Year 2014.
Cardiome Pharma Corp. Key Developments
Cardiome Pharma Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 13 15
Cardiome Pharma Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $3.9 million or $0.23 per share compared to a net loss of $3.1 million or $0.20 per share for the three months ended March 31, 2014. Revenue was $5.5 million, compared to $7.6 million a year ago. The decrease was due primarily to foreign exchange, timing of distributor sales, and a decrease in AGGRASTAT® sales due to generic competition. Operating loss was $2.657 million against $2.681 million a year ago. Loss before income taxes was $3.780 million against $3.017 million a year ago. Net cash used in operating activities was $3.168 million against $9.294 million a year ago. Purchase of property and equipment were $0.89 million against $0.3 million a year ago. Increase in intangible assets was $0.13 million against $0.12 million a year ago.
Cardiome and AOP Orphan Pharma Enter ESMOCARD Commercialization Agreement
May 12 15
Cardiome Pharma Corp. announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride) in Italy, France, Spain and Belgium. Financial details of the agreement were not disclosed.
Cardiome Pharma Corp. to Report Q1, 2015 Results on May 13, 2015
May 7 15
Cardiome Pharma Corp. announced that they will report Q1, 2015 results at 8:00 AM, US Eastern Standard Time on May 13, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries